Study identifier:D798VC00001
ClinicalTrials.gov identifier:NCT06792695
EudraCT identifier:N/A
CTIS identifier:2024-518469-84-00
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants with Colorectal Cancer (CANTOR)
Metastatic Colorectal Cancer
Phase 2
No
Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab
All
120
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jan 2025 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Volrustomig + FOLFIRI+ Bevacizumab group (Arm A) Participants will receive FOLFIRI and bevacizumab together with volrustomig. | Drug: Volrustomig Volrustomig will be administered as intravenous (IV) infusion. Other Name: MEDI5752 Drug: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) FOLFIRI will be administered as IV infusion. Drug: Bevacizumab Bevacizumab will be administered as IV infusion. |
Active Comparator: FOLFIRI+ BEVACIZUMAB group (Arm B) Partcipants will receive FOLFIRI and bevacizumab. | Drug: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) FOLFIRI will be administered as IV infusion. Drug: Bevacizumab Bevacizumab will be administered as IV infusion. |